Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578697 | 0.90 | CXCR3 (0.52) | CXCR3CCR1MEN1KMT2ALMNA | |
| SCHEMBL5577629 | 0.85 | ALDH1A1 (0.53) | CXCR3LMNAPOLBSMN1; SMN2 | |
| SCHEMBL5577730 | 0.85 | CCR1 (0.48) | CXCR3CCR1MEN1KMT2ADRD2 | |
| SCHEMBL5577690 | 0.85 | CXCR3 (0.58) | CXCR3CCR1MEN1KMT2A | |
| SCHEMBL5577303 | 0.83 | CCR1 (0.50) | CXCR3CCR1MEN1KMT2APOLB | |
| SCHEMBL5577919 | 0.82 | MT-CO2 (0.52) | CCR1MEN1KMT2ALMNACYP1A2 | |
| SCHEMBL5577669 | 0.82 | CXCR3 (0.50) | CXCR3CCR1MEN1KMT2A | |
| SCHEMBL5577638 | 0.82 | CXCR3 (0.50) | CXCR3CCR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5577570 | 0.80 | SMN1; SMN2 (0.53) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL5577873 | 0.80 | DRD2 (0.53) | CCR1MEN1KMT2ADRD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CXCR3 32/4885CCR1 103/4885MEN1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.